X4 Pharmaceuticals Inc (XFOR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.24+2.21%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · XFOR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 135.1% |
| Our one-year growth estimate | diamond | 26.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 108.5 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers
XFOR — capital allocation — Creation of a Direct Financial Obligation or an Obligation under an Off-Balan…
Dated 2026-10-08
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Why it matters: This trial tests whether patients can lower or stop G-CSF while taking mavorixafor. Its start would move that plan into testing.
Supportive ifX4 reports the first patient visit in 4STEPS by March 31, 2027.
Worry ifX4 reports no first patient visit by March 31, 2027, or delays the start beyond Q1 2027.
Why it matters: X4 has reported operating losses, and the added loan money depends on K2 approval and other terms. Funding would add cash; failure to access it would leave less room to fund its plans.
Watch forX4 discloses that K2 approved and funded the extra $70 million tranche.
Also watch forX4 discloses that K2 denied the extra tranche, or that X4 cannot meet the loan terms needed to draw it.
Why it matters: This is the next key trial step. A delay could push back the planned Q1 2028 results.
Supportive ifX4 reports that all 126 patients are enrolled by December 31, 2026.
Worry ifX4 reports fewer than 126 patients enrolled by December 31, 2026, or delays the target.
Why it matters: The planned trial measures lower G-CSF use after mavorixafor starts. Clear dose cuts would support the treatment plan.
Supportive ifAt the H1 2028 readout, X4 reports the share of patients who stopped G-CSF or cut their dose by at least 75% at six months.
Worry ifThe H1 2028 readout shows few patients stopped G-CSF or cut their dose by at least 75%, or reports safety concerns with dose cuts.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$191 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $709 loss on $10,000 · 7.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,754 loss on $10,000 · 47.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The trial must show a rise in neutrophil counts and fewer infections. Failure on either goal would weaken the case for use in chronic neutropenia.
Supportive ifIn Q1 2028 results, X4 reports a positive ANC response and a lower annualized infection rate than placebo. It met both main goals.
Worry ifThe Q1 2028 results miss either main goal, or X4 delays the results beyond H1 2028.